Siemens Healthineers AG: Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052
January 25, 2021 at 11:18 am EST
Share
DGAP-News: Siemens Healthineers AG
/ Key word(s): Share Buyback
Siemens Healthineers AG: Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052
25.01.2021 / 17:16
The issuer is solely responsible for the content of this announcement.
Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052
Share buyback - 8th Interim Reporting
In the time period from and including 18 January 2021 until and including 22 January 2021, a number of 131,964 shares of Siemens Healthineers AG were bought back within the framework of the share buyback of Siemens Healthineers AG; on 03 October 2020, Siemens Healthineers AG disclosed pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014 (MAR) and Art. 2 para. 1 of the Delegated Regulation (EU) No. 2016/1052 the start of the share buyback on 07 October 2020.
Shares were bought back as follows:
Day of purchase
Aggregated volume of shares
Weighted average price
01/20/2021
27,411
44.4576
01/21/2021
55,082
44.6668
01/22/2021
49,471
44.5061
The transactions are published in a detailed form on the website of Siemens Healthineers AG (www.corporate.siemens-healthineers.com/investor-relations).
The total volume of shares which were bought back within the framework of the share buyback in the time period from and including 07 October 2020 until and including 22 January 2021 amounts to 3,487,877 shares.
The purchase of the shares of Siemens Healthineers AG is carried out by a credit institution that has been commissioned by Siemens Healthineers AG; the shares are repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA).
Munich, 25 January 2021
Siemens Healthineers AG
The Managing Board
25.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Siemens Healthineers AG
Henkestr. 127
91052 Erlangen
Germany
Phone:
+49 800 188 188 5
Fax:
+49 9131 844552
E-mail:
contact@healthcare.siemens.com
Internet:
https://www.corporate.siemens-healthineers.com
ISIN:
DE000SHL1006
WKN:
SHL100
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Siemens Healthineers AG is one of the world's No.1 manufacturers of equipment for medical imaging, laboratory diagnostics and hospital information systems. In addition, the group is developing digital health services and services dedicated to health establishments. Net sales break down by activity as follows:
- sale of imaging equipment and solutions (53%);
- sale of diagnostic equipment (21%);
- sale of solutions and services for cancer care (16.6%);
- sale of advanced therapeutic solutions (9.4%): for image-guided minimally invasive treatments in the areas of cardiology, interventional radiology and surgery.
Net sales are distributed geographically as follows: Germany (4.9%), Europe/CIS/Africa/Middle East (27.3%), the United States (34.6%), America (6.3%), China (13%) and Asia/Pacific and Japan (13.9%).
SIEMENS HEALTHINEERS AG 
